Chengdu Easton Biopharmaceuticals Co Ltd (688513) — Cash Flow-to-Debt Ratio
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Cash Flow-to-Debt Ratio of 0.09x as of September 2025, meaning its operating cash flow of CN¥61.35 Million could theoretically repay 0% of its total liabilities (CN¥692.94 Million) in one year. See Chengdu Easton Biopharmaceuticals Co Ltd (688513) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chengdu Easton Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Chengdu Easton Biopharmaceuticals Co Ltd across 12 annual periods. Also explore 688513 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Chengdu Easton Biopharmaceuticals Co Ltd. For market capitalisation and broader financial context, see 688513 market cap.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.37x | CN¥263.24 Million | CN¥702.21 Million | ▲ +1.2% |
| 2023 | 0.37x | CN¥275.25 Million | CN¥743.33 Million | ▲ +39.7% |
| 2022 | 0.27x | CN¥151.94 Million | CN¥573.08 Million | ▼ -13.1% |
| 2021 | 0.31x | CN¥147.60 Million | CN¥483.60 Million | ▼ -15.1% |
| 2020 | 0.36x | CN¥156.52 Million | CN¥435.61 Million | ▼ -26.6% |
| 2019 | 0.49x | CN¥141.83 Million | CN¥289.64 Million | ▼ -39.1% |
| 2018 | 0.80x | CN¥166.79 Million | CN¥207.50 Million | ▲ +37.6% |
| 2017 | 0.58x | CN¥85.70 Million | CN¥146.70 Million | ▼ -28.2% |
| 2016 | 0.81x | CN¥106.06 Million | CN¥130.43 Million | ▼ -30.2% |
| 2015 | 1.16x | CN¥50.57 Million | CN¥43.42 Million | ▲ +99.1% |
| 2014 | 0.59x | CN¥46.71 Million | CN¥79.85 Million | ▲ +79.4% |
| 2013 | 0.33x | CN¥28.12 Million | CN¥86.24 Million | — |